Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT04494425
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
866 Enrollment(s)
293 Study location(s)
INTERVENTIONAL (PHASE3)
Advanced or Metastatic Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04294628
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
62 Enrollment(s)
6 Study location(s)
INTERVENTIONAL (PHASE1)
Advanced Malignant Solid Neoplasm


Metastatic Malignant Solid Neoplasm


Refractory Malignant Solid Neoplasm


Unresectable Malignant Solid Neoplasm
COMPLETED
NCT03523585
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
608 Enrollment(s)
227 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
ACTIVE_NOT_RECRUITING
NCT06100874
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
28 Enrollment(s)
4 Study location(s)
INTERVENTIONAL (PHASE2)
Her 2 Positive Breast Cancer


Breast Cancer Female


Breast Cancer Metastatic
RECRUITING
NCT06058988
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
30 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Brain Cancer


Glioblastoma


Metastatic Cancer


Leptomeningeal Metastasis


Recurrent Glioblastoma
NOT_YET_RECRUITING
NCT07416253
Trastuzumab Rezetecan vs Trastuzumab Deruxtecan in the Neoadjuvant Treatment of HER2 Positive Breast Cancer
68 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
WITHDRAWN
NCT06585969
A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer
0 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE3)
Metastatic Breast Cancer


ER-positive Breast Cancer


Luminal B


Her2 Enriched


Basal Like
RECRUITING
NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
550 Enrollment(s)
166 Study location(s)
INTERVENTIONAL (PHASE3)
Metastatic HER2-positive Breast Cancer